Celldex Therapeutics, Inc. (Nasdaq: CLDX) has announced the commencement of an underwritten public offering for the sale of 10,345,000 shares of its common stock at a public offering price of $29.00 per share. The offering is expected to generate approximately $300 million in gross proceeds, excluding underwriting discounts and commissions. The company has also granted the underwriters a 30-day option to purchase up to an additional 1,551,750 shares of common stock. The net proceeds from this offering are intended to be used for various purposes, including funding ongoing commercial readiness activities and the commercial launch of barzolvolimab, if approved, as well as for the continued development of its product candidates and general corporate purposes. The offering is anticipated to close on or about April 6, 2026, subject to customary closing conditions. Leerink Partners LLC and TD Cowen are acting as joint bookrunning managers for the offering. This public offering follows the company's recent filing of a prospectus supplement to its automatically effective shelf registration statement on Form S-3, which was previously filed with the SEC. The company is committed to ensuring compliance with all applicable regulations and has taken steps to maintain transparency with its investors throughout this process.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.